We are live on
!
Find out more
MACM
March Altus Capital Management Portfolio holdings
AUM
$16M
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter
Est. Return
+10.88%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$12.9M
AUM Growth
+$3.27M
(+34%)
Cap. Flow
+$2.55M
Cap. Flow
% of AUM
19.73%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
3
Reduced
1
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$2.05M |
| 2 |
Johnson & Johnson
JNJ
|
+$1.48M |
| 3 |
Align Technology
ALGN
|
+$914K |
| 4 |
Edwards Lifesciences
EW
|
+$120K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$826K |
| 2 |
ATHN
Athenahealth, Inc.
ATHN
|
+$680K |
| 3 |
DexCom
DXCM
|
+$500K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.33% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Acadia Pharmaceuticals
ACAD
$4.55B
| $2.69M | 20.75% |
82,723
+61,171
| +284% | +$2.05M |
|
2
Eli Lilly
LLY
$1.03T
| $2.11M | 16.32% |
26,810
| – | – |
|
|
3
Edwards Lifesciences
EW
$50B
| $1.86M | 14.35% |
55,833
+3,504
| +7% | +$120K |
|
|
4
Johnson & Johnson
JNJ
$617B
| $1.58M | 12.19% |
+13,000
| New | +$1.48M |
|
|
5
Align Technology
ALGN
$12.4B
| $1.4M | 10.78% |
17,319
+11,953
| +223% | +$914K |
|
|
PETX
6
DELISTED
Aratana Therapeutics, Inc.
PETX
| $1.38M | 10.67% |
218,515
| – | – |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
| $1M | 7.76% |
8,599
| – | – |
|
|
8
DexCom
DXCM
$28.8B
| $928K | 7.17% |
46,800
-29,384
| -39% | -$500K |
|
|
9
Regeneron Pharmaceuticals
REGN
$77.4B
| – | – |
-2,291
| Closed | -$826K |
|
|
ATHN
10
DELISTED
Athenahealth, Inc.
ATHN
| – | – |
-4,900
| Closed | -$680K |
|
Similar funds
IC
PA
GMIM
JHWCP
SMPIAI
NCMG
CAD
GPI
March Altus Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, March Altus Capital Management held 10 positions worth $12.9M, up 34% from $9.66M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
March Altus Capital Management deployed $2.55M of net new capital in Q2 2016, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Johnson & Johnson: 13,000 shares worth $1.58M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 80% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was DexCom, an estimated $500K trimmed.
- March Altus Capital Management's largest Q2 2016 buy was Johnson & Johnson: 13,000 shares worth $1.58M.
- March Altus Capital Management added most to Acadia Pharmaceuticals in Q2 2016, an estimated $2.05M increase.
- March Altus Capital Management's biggest Q2 2016 reduction was DexCom, cutting an estimated $500K.
- March Altus Capital Management fully exited Regeneron Pharmaceuticals in Q2 2016, selling an estimated $826K.
- March Altus Capital Management's ten largest holdings make up 100% of its $12.9M portfolio in Q2 2016.
- March Altus Capital Management opened 1 new position and closed 2 in Q2 2016.
- March Altus Capital Management's portfolio value rose 34% quarter-over-quarter to $12.9M.
Based on March Altus Capital Management's 13F filing for Q2 2016, filed 27 Jul 2016.